Department of Digestive Surgery, Hôpital Saint Antoine, 184, rue du faubourg Saint Antoine, 75012 Paris, France.
Ann Surg Oncol. 2013 Jul;20(7):2405-12. doi: 10.1245/s10434-012-2861-x. Epub 2013 Jan 23.
Recent data support liver resection (LR) as first-line approach in patients with preserved liver function who have resectable/transplantable hepatocellular carcinoma (HCC). This study was designed to evaluate the outcome of LR in patients with transplantable HCC.
Between 1998 and 2009, 75 patients (65 men, mean age 61 ± 11 years) with HCC eligible for liver transplantation (LT) underwent LR. The underlying hepatic disease was related to hepatitis C (HCV) in 30 (40 %) patients, hepatitis B (HBV) in 15 (20 %) patients, alcohol abuse in 26 patients (36 %) and other in 10 patients (13 %). Fifty-five (73 %) patients had cirrhosis. Intermittent clamping of the hepatic pedicle was used in 41 (55 %) patients. Treatment of recurrence by salvage LT was performed in 6 (8 %) patients.
Operative morbidity and mortality rates were 37 and 5 % respectively. At 1, 3, and 5 years, overall (OS) and disease-free (DFS) survival rates were 81, 69,55 and 56, 31, and 21 %, respectively. On multivariate analysis, HCV infection was the only independent factor associated with decreased OS (p = 0.02). On multivariate analysis, HCV infection (p = 0.05) and intermittent hepatic pedicle clamping (p = 0.003) were associated with decreased DFS. The 1-, 3-, and 5-year OS and DFS rates in patients with HCV-related HCC were 69, 53, 38 and 50, 18, and 9% respectively.
Overall and disease-free survival after liver resection in patients with HCV-related HCC and preserved liver function is poor. Primary LT should be offered to these patients.
最近的数据支持在肝功能正常且可切除/可移植的肝细胞癌(HCC)患者中,采用肝切除术(LR)作为一线治疗方法。本研究旨在评估可移植 HCC 患者接受 LR 的结果。
1998 年至 2009 年,75 例符合肝移植(LT)条件的 HCC 患者接受了 LR。其中 30 例(40%)患者的基础肝脏疾病与丙型肝炎(HCV)有关,15 例(20%)患者与乙型肝炎(HBV)有关,26 例(36%)患者与酒精滥用有关,10 例(13%)患者与其他原因有关。55 例(73%)患者有肝硬化。41 例(55%)患者采用间歇性肝蒂夹闭。6 例(8%)患者因复发而行挽救性 LT 治疗。
手术发病率和死亡率分别为 37%和 5%。1、3 和 5 年的总生存率(OS)和无病生存率(DFS)分别为 81%、69%、55%和 31%、21%。多因素分析显示,HCV 感染是与 OS 降低相关的唯一独立因素(p=0.02)。多因素分析显示,HCV 感染(p=0.05)和间歇性肝蒂夹闭(p=0.003)与 DFS 降低相关。HCV 相关 HCC 患者的 1、3 和 5 年 OS 和 DFS 率分别为 69%、53%、38%和 50%、18%和 9%。
HCV 相关 HCC 且肝功能正常的患者接受 LR 后总体生存率和无病生存率较差。应向这些患者提供原发性 LT。